Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

FDA OKs CoreValve for high-risk patients

The FDA approved the CoreValve device for transcatheter aortic valve replacement (TAVR) in high-risk patients with severe aortic stenosis without a review from an expert panel. While the favorable decision was expected, the road to it developed a few potholes.

Thumbnail

Tool IDs patients with poor outcomes after TAVR

A model that includes quality of life (QoL) in its assessment predicted with moderate discrimination patients who likely would have poor outcomes after undergoing transcatheter aortic valve replacement (TAVR), according to results published online May 23 in Circulation.

Thumbnail

TAVR triumphs

This week, two titans in transcatheter aortic valve replacement (TAVR) settled a feud over patents. One beneficiary of that agreement may be TAVR itself.

Boston Scientific Lotus Valve System demonstrates strong performance and safety profile at six months

Further validating its advanced transcatheter aortic valve implantation (TAVI) technology, the Boston Scientific Corporation Lotus Valve System continued to demonstrate impressive performance at six months, according to new data presented at EuroPCR 2014 in Paris.

Medtronic CoreValve System demonstrates positive clinical performance at two years in 'real world' ADVANCE study

Medtronic, Inc. today revealed new data showing that patients treated with the CoreValve System experienced positive clinical outcomes in the rigorous "real world" Medtronic CoreValve ADVANCE Study. Presented at EuroPCR 2014, the transcatheter aortic valve implantation (TAVI) study revealed low rates of mortality and stroke, and showed exceptional valve performance through two years.

TAVR détente: Edwards, Medtronic settle patent dispute

Edwards Lifesciences and Medtronic reached a cross-license settlement over transcatheter aortic valve replacement (TAVR) devices with provisions that should put their patent dispute to rest.

CMS supports coverage for transcatheter mitral devices

The Centers for Medicare & Medicaid Services (CMS) is proposing to cover transcatheter mitral valve repair, but only if certain conditions are met.

St. Jude Medical Aanounces first implants in US study of the Portico Transcatheter Aortic Heart Valve System

St. Jude Medical, Inc., a global medical device company, today announced that the first patient implants occurred in the Portico Re-sheathable Transcatheter Aortic Valve System U.S. IDE Trial (PORTICO trial). The trial is evaluating the Portico Transcatheter Aortic Valve System, the first aortic heart valve that is repositionable until fully deployed. The trial will enroll patients who are considered to have a high or an extreme surgical risk (meaning they would not be considered) for open-heart surgery.

Displaying 1249 - 1256 of 2350

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.